Proteolysis Targeting Chimera (PROTAC) technology has transitioned from a theoretical breakthrough to a cornerstone of modern oncology, fundamentally altering how…
Read More
Evogene and ELEO Forge Strategic Alliance to Pioneer Next-Generation Oral PCSK9 Inhibitors for Cardiovascular Disease
Evogene and ELEO have officially announced a significant scientific collaboration poised to accelerate the discovery and development of novel oral…
Read More
Pens to pills: what oral GLP-1s change at the bench
The pharmaceutical landscape for metabolic diseases is undergoing a profound transformation, heralded by the recent approval of orforglipron, the first…
Read More
Weekly Gilead and Merck oral HIV regimen maintains suppression in two phase 3 trials
Recent findings presented at the 26th International AIDS Conference have underscored a significant advancement in HIV treatment, with an investigational…
Read More
Novo Nordisk Secures European Approval for Oral Wegovy, Bolstering First-Mover Advantage in Obesity Pill Market
Novo Nordisk has solidified its pioneering position in the burgeoning market for oral obesity medications with the European Commission’s marketing…
Read More
MSD Secures Landmark Approval for First Oral PCSK9 Inhibitor, Ushering in New Era for Cholesterol Management and Strategic Diversification
The pharmaceutical landscape has been significantly reshaped with MSD (Merck & Co.) achieving a monumental victory: the US Food and…
Read More
Pens to Pills: The Transformative Era of Oral GLP-1 Receptor Agonists in Drug Discovery and Patient Care
The pharmaceutical landscape for metabolic diseases has reached a pivotal inflection point, marked by the recent approval of the first…
Read More
The Oral GLP-1 Revolution: Unpacking the Scientific and Clinical Impact of Small Molecules
The pharmaceutical landscape for metabolic disorders, particularly Type 2 Diabetes and obesity, is undergoing a profound transformation, heralded by the…
Read More
Pens to pills: what oral GLP-1s change at the bench
The pharmaceutical landscape for metabolic disorders is undergoing a profound transformation, heralded by the advent of oral small-molecule GLP-1 receptor…
Read More
LG AI Research and D&D Pharmatech Forge Landmark Partnership to Revolutionize Oral Peptide Drug Delivery Through Artificial Intelligence
LG AI Research and D&D Pharmatech have officially inked a pivotal agreement, signaling a new era in pharmaceutical innovation with…
Read More
